Literature DB >> 8597045

Bcl-2 family proteins: regulators of chemoresistance in cancer.

J C Reed1.   

Abstract

Knowledge about the mechanisms that regulate the expression of the family of BCL-2 genes and the biochemical characteristics of their encoded proteins is beginning to provide new insights into the origins of cancer and our all too often inability to adequately treat it. With better understanding of the functional significance of these protein-protein interactions involving Bcl-2, Bax, and other members of the Bcl-2 protein family and with insights into the structural details of these interactions, it may eventually be possible to develop novel pharmacological agents that improve tumor responses to currently available anticancer drugs and that have other clinically relevant uses as well.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8597045     DOI: 10.1016/0378-4274(95)03551-6

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  18 in total

1.  Effect of hemorrhagic shock on apoptosis and energy-dependent efflux system in the brain.

Authors:  Zhao-Ying Yu; Shinsuke Ono; Maria Spatz; Richard M McCarron
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

2.  ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.

Authors:  Qing-Huan Lin; Fu-Chang Que; Chun-Ping Gu; De-Sheng Zhong; Dan Zhou; Yi Kong; Le Yu; Shu-Wen Liu
Journal:  Acta Pharmacol Sin       Date:  2017-07-10       Impact factor: 6.150

3.  Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

Authors:  Rathi N Pillai; Joseph Aisner; Suzanne E Dahlberg; John S Rogers; Robert S DiPaola; Seena Aisner; Suresh S Ramalingam; Joan H Schiller
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-24       Impact factor: 3.333

4.  Programmed cell death (apoptosis) in cord blood lymphocytes.

Authors:  S Aggarwal; A Gupta; S Nagata; S Gupta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

5.  Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.

Authors:  G Deng; C Lane; S Kornblau; A Goodacre; V Snell; M Andreeff; A B Deisseroth
Journal:  Mol Med       Date:  1998-03       Impact factor: 6.354

Review 6.  Biomarkers of therapeutic response to BCL2 antagonists in cancer.

Authors:  Lloyd T Lam; Haichao Zhang; Brenda Chyla
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

7.  Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.

Authors:  Jacob J Junco; Anna Mancha; Gunjan Malik; Sung-Jen Wei; Dae Joon Kim; Huiyun Liang; Thomas J Slaga
Journal:  Mol Cancer Res       Date:  2013-09-26       Impact factor: 5.852

8.  Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).

Authors:  Shinichi Kitada; Christina L Kress; Maryla Krajewska; Lee Jia; Maurizio Pellecchia; John C Reed
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

9.  Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.

Authors:  Meiyan Sun; Qunshu Zhang; Xiaoyu Yang; Steven Y Qian; Bin Guo
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

10.  A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells.

Authors:  Yee-Joo Tan; Eileen Teng; Anthony E Ting
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.